To the Editor In response to the US Preventive Services Task Force recommendation statement on the insufficient evidence regarding benefits and harms of screening for atrial fibrillation with electrocardiography (ECG),1 Mandrola and colleagues2 discuss the potential harms and lack of efficacy of screening for atrial fibrillation. Although some physicians and physician groups may recommend this screening,3 we should be concerned that the general public may have easy access to this screening test, in addition to other screenings that lack clinical evidence and consensus, through direct-to-consumer (DTC) screening companies.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Wallace EA. Direct-to-Consumer Atrial Fibrillation Screening. JAMA Intern Med. 2019;179(1):121–122. doi:10.1001/jamainternmed.2018.6972
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: